2'-O-acetyl-3-descladinosyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate | 675831-89-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2'-O-acetyl-3-descladinosyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate
• 英文别名: 2'-O-acetyl-3-decladinosyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate；2'-O-acetyl-3-decladinosyl-3-oxy-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate
• CAS: 675831-89-7
• 化学式: C₃₄H₆₀N₂O₁₁
• 分子量: 672.857
• InChiKey: GWYCCWAOBDNZMT-OMVVIJMGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.12
• 重原子数：
  47.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  153.53
• 氢给体数：
  2.0
• 氢受体数：
  12.0

反应信息

• 作为反应物：
  描述：

  2'-O-acetyl-3-descladinosyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate 在 三氟乙酸吡啶 、 二甲基亚砜 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成
  参考文献：
  名称：

  Fajdetic, Andrea; Kobrehel, Gabrijela; Lazarevski, Gorjana, Croatica Chemica Acta, 2009, vol. 82, # 4, p. 715 - 723

  摘要：

  DOI：
• 作为产物：
  描述：

  12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate 在 盐酸 、 碳酸氢钠 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 52.0h， 生成 2'-O-acetyl-3-descladinosyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate
  参考文献：
  名称：

  Fajdetic, Andrea; Kobrehel, Gabrijela; Lazarevski, Gorjana, Croatica Chemica Acta, 2005, vol. 78, # 2, p. 301 - 312

  摘要：

  DOI：

文献信息

• [EN] THE PRESENT INVENTION RELATES TO THE NEW 3-DECLADINOSYL DERIVATIVES OF 9-DEOXO-9A-AZA­9A-HOMOERYTHROMYCIN A 9A,11-CYCLIC CARBAMATES<br/>[FR] NOUVEAUX DERIVES 3-DECLADINOSYL DE CARBAMATES 9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCINE A 9A,11-CYCLIQUES
  申请人：PLIVA D D

  公开号：WO2004029067A1

  公开（公告）日：2004-04-08

  The present invention relates to the new 3-decladinosyl derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate of the general formula (I), their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein R1 individually stands for hydrogen, hydroxyl or a group of the formula (II), wherein X individually stands for C1-C6alkyl group, C2-C6alkenyl group or X individually stands for C1-C6alkyl group with at least one incorporated O, S or N atom or X individually stands for (CH2)n-Ar or X individually stands for (CH2)n-heterocycloalkyl, wherein (CH2)n individually stands for alkyl, wherein n is 1-10, with or without incorporated atom O, S or N, wherein Ar individually stands for 5-10-membered monocyclic or bycyclic aromatic ring with 0-3 atom O, S or N, unsubstituted or substituted with 1-3 group, which are selected independently from halogen, OH, OMe, NO2, NH2, amino--C1-C3alkyl or amino-C1-C3dialkyl, CN, SO2NH2, C1-C3alkyl, and heterocycloalkyl stands for unaromatic, partially or completely saturated 3-10-membered monocyclic or bicyclic ring system, which includes 3-8-membered monocyclic or bicyclic ring, which includes 6-membered aromatic or heteroaromatic ring connected with a unaromatic ring with or without incorporated O, S or N atom, unsubstituted or substituted with 1-4 group, which are selected independently from halogen, OH, OMe, NO2, NH2, amino--C1-C3alkyl or amino-Cl-C3dialkyl, CN, SO2NH2, C1-C3alkil, -C(O)-, COOH or R1 together with R2 stands for ketone, R2 individually stands for hydrogen or together with R1 stands for ketone or together with R3 stands for ether, R3 individually stands for hydroxyl, a group of the formula -OX or together with R2 stands for ether, R4 individually stands for hydrogen, C1-C4alkyl group or C2-C4alkenyl group, and R5 individually stands for hydrogen or hydroxyl protected group, to intermediates for synthesis of other macrolide compounds with antibacterial activity, to the proces for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to the process for the preparation of pharmaceutical compositions, as well as the use of pharmaceutical compositions for treating bacterial infections.

  本发明涉及新的9-去氧-9a-氮杂-9a-同蚓霉素A 9a,11-环氨基甲酸酯的3-脱氯基衍生物的一般式(I)，它们与无机或有机酸的药学上可接受的加合物盐以及它们的水合物，其中R1分别代表氢、羟基或式(II)的基团，其中X分别代表C1-C6烷基基团、C2-C6烯基基团或X分别代表至少含有一个O、S或N原子的C1-C6烷基基团，或者X分别代表(CH2)n-Ar或X分别代表( )n-杂环烷基，其中( )n分别代表烷基，n为1-10，或有或无含有原子O、S或N，其中Ar分别代表含有0-3个原子O、S或N的5-10元单环或双环芳香环，未取代或取代1-3个基团，这些基团独立选择自卤素、羟基、OMe、NO2、NH2、氨基-C1-C3烷基或氨基-C1-C3二烷基、CN、SO2NH2、C1-C3烷基，而杂环烷基代表非芳香、部分或完全饱和的3-10元单环或双环环系，其中包括3-8元单环或双环环，其中包括与不含有或含有1-4个基团的未取代或取代6元芳香或杂芳香环相连接的非芳香环，这些基团独立选择自卤素、羟基、OMe、 、NH2、氨基-C1-C3烷基或氨基-C1-C3二烷基、CN、SO2NH2、C1-C3烷基、-C(O)-、COOH或R1与R2一起代表酮，R2分别代表氢，或与R1一起代表酮，或与R3一起代表醚，R3分别代表羟基、-OX的基团或与R2一起代表醚，R4分别代表氢、C1-C4烷基或C2-C4烯基，R5分别代表氢或羟基保护基团，用于合成具有抗菌活性的其他大环内酯化合物的中间体，用于它们的制备过程，用于它们与无机或有机酸的药学上可接受的加合物盐以及它们的水合物，用于制备药物组合物的制备过程，以及用于治疗细菌感染的药物组合物的使用。